Administration of TRPM8 agonists in the colitis models inhibited TRPV1-dependent CGRP expression, reduced pro-inflammatory cytokines, and attenuated the common hallmarks of colitis such as bowel thickness and infiltration of granulocytes. Here, TRPM8 is linked to colitis.